It is not surprising that the U.S. Food and Drug Administration (USFDA) has a hardcore stance on cannabis in general. It is likely for that reason that they have shown no favor to CBD thus far.
However, the CBD trend is one of the fastest-growing movements in the entire cannabis industry. And that’s saying a lot. As cannabis legalization sweeps across NA (ok, slowly spreads across NA is more accurate), the CBD niche is shown to create an extremely high demand.
What exactly is CBD, you might ask? To sum it up as quickly and neatly as possible, the two most sought after compounds found in cannabis (otherwise known as cannabinoids) are THC and CBD.
THC is the one that derives mainly from the cannabis plant, CBD is found in its highest concentrations in hemp plants. The THC compound is famous for causing the euphoric feeling of being “high.”
CBD, on the other hand, is the compound that is more sought after for its medicinal properties, such as relieving pain and soreness. It also lacks the quality of THC which is known to get you “stoned.”
To date, companies have shown interest in CBD for products ranging from beverages (alcoholic and non-alcoholic) to ointments, vapes, a range of oils, and more.
Sounds like a great thing, right? Well, it could be, but things aren’t so simple.
Recently, Curaleaf Holdings received a letter from the USFDA stating that the companies products containing CBD in any shape or form were unapproved, unsafe, and in direct violation of the Federal Food, Drug, and Cosmetic Act.
The items flagged by the USFDA included everything from pain-relief patches and various tinctures to vape pens, lotions, and other CBD-products.
To be specific, the USFDA wrote that their company (Curaleaf Holdings) is “illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain, and pet anxiety, among other conditions or diseases.”
It is uncertain what the future of CBD in the United States will look like. CVS, Walgreens, and Rite Aid are all currently planning to launch CBD products onto the shelves of hundreds of stores. But, with recent happenings, who’s to say how things will go from here.
One thing is for certain; Curaleaf Holdings is the first company to draw the attention of the USFDA on such matters as CBD, but it won’t be the last.